Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pemetrexed
Drug ID BADD_D01701
Description Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated.
Indications and Usage Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Marketing Status approved; investigational
ATC Code L01BA04
DrugBank ID DB00642
KEGG ID D07472
MeSH ID D000068437
PubChem ID 135410875
TTD Drug ID D0Y4GO
NDC Product Code 16729-244; 0338-0722; 0409-0021; 70121-1233; 47848-026; 65129-1366; 55150-383; 0409-3532; 55150-381; 0409-1045; 68001-537; 0409-0020; 0409-1061; 0480-4514; 16729-230; 55150-382; 68001-547; 0480-4515; 0480-4516; 0338-0720; 16729-229; 68001-535; 68001-549; 0409-0004; 0409-2188; 68001-536; 42367-531; 68001-548; 0409-1060; 70121-1232
UNII 04Q9AIZ7NO
Synonyms Pemetrexed | MTA | N-(4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid | Pemetrexed Disodium | Disodium, Pemetrexed | LY 231514 | 231514, LY | LY-231,514 | LY231514 | LY 231,514 | 231,514, LY | LY-231514 | Alimta
Chemical Information
Molecular Formula C20H21N5O6
CAS Registry Number 137281-23-3
SMILES C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.000112%
Abdominal pain07.01.05.0020.000448%
Acute myocardial infarction02.02.02.001; 24.04.04.0010.000112%-
Adenocarcinoma16.16.01.0040.000112%-
Adrenal disorder05.01.03.001---
Agranulocytosis01.02.03.001---
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.001--
Anaemia01.03.02.0010.001421%
Anaphylactic shock10.01.07.002; 24.06.02.0040.000392%-
Angina pectoris02.02.02.002; 24.04.04.002--
Aphasia17.02.03.001; 19.21.01.0010.000112%
Arrhythmia02.03.02.001---
Arrhythmia supraventricular02.03.03.001---
Arthralgia15.01.02.001--
Ascites02.05.04.002; 07.07.01.001; 09.01.05.0030.000168%
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.0010.001052%-
Atrial fibrillation02.03.03.0020.000616%
Blood creatinine decreased13.13.01.003---
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001---
Bronchospasm10.01.03.012; 22.03.01.0040.000112%
Capillary leak syndrome08.01.07.012; 24.06.03.0010.000112%
Cardiac arrest02.03.04.0010.000280%
Cardiac failure02.05.01.0010.000168%
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000112%-
Cerebral infarction17.08.01.004; 24.04.06.0020.000168%-
Cerebrovascular accident17.08.01.007; 24.03.05.0010.000280%
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.0020.000112%-
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages